Trevi Therapeutics (TRVI) Q4 2025: $188M Cash Runway Extends to 2028, Phase 3 Trials Set for Launch
Trevi Therapeutics enters 2026 with a clear regulatory path, robust funding, and parallel pivotal trials for IPF-related chronic cough. The company’s recent FDA alignment and $188 million cash position set the stage for accelerated execution across multiple chronic cough indications. Investors now face a pivotal period as Trevi launches three major trials and expands its clinical and commercial footprint.
Summary
- Regulatory Clarity Secured: FDA alignment on IPF chronic cough enables parallel Phase 3 launches.
- Capital Strength: $188 million cash runway funds key data readouts through 2028.
- Pipeline Expansion: Non-IPF ILD and RCC programs advance, doubling market potential.
Performance Analysis
2025 marked a decisive inflection for Trevi Therapeutics, driven by positive late-stage data in both the CORAL (IPF-related chronic cough) and RIVER (refractory chronic cough, RCC) trials. These results enabled the company to raise capital and secure an end-of-year cash position of $188 million, providing a self-funded runway into 2028. This capital will support pivotal data readouts for the company’s three lead programs: IPF-related chronic cough, non-IPF interstitial lung disease (ILD) chronic cough, and RCC.
The company’s financial discipline was highlighted by the CFO, who underscored efficient capital deployment and a specialty-focused commercial model that limits overhead. Trevi’s cash is earmarked for parallel Phase 3 programs, with the first IPF-related chronic cough trial set to enroll 300 patients globally and a confirmatory 130-patient trial to follow. The upcoming non-IPF ILD and RCC trials are also fully funded through key milestones, positioning Trevi to deliver top-line data across indications without near-term financing risk.
- Trial Launch Cadence: Both pivotal IPF trials will run in parallel, accelerating time to NDA submission.
- Market Expansion: Non-IPF ILD program targets a patient pool over twice the size of IPF, leveraging shared pulmonologist networks.
- Operational Leverage: Specialty focus and overlapping trial infrastructure create cost and execution synergies.
Trevi’s execution on both clinical and financial fronts sets up a critical period of value creation as multiple data catalysts approach, and the company’s strategic sequencing of trials aims to maximize both regulatory and commercial leverage.
Executive Commentary
"2025 was a major inflection point for growth at Trevi, driven by our positive data readouts in both the CORAL trial in patients with idiopathic pulmonary fibrosis or IPF-related chronic cough, and the RIVER trial in patients with refractory chronic cough or RCC. As a result of these data, we were able to raise capital, setting us up nicely for the next round of trials for each of our indications."
Jennifer Good, President and CEO
"We ended 2025 with approximately $188 million in cash, cash equivalents, and marketable securities, which gives us an expected runway into 2028. This runway allows us to provide top-line data in our key clinical trials."
David Hastings, Chief Financial Officer
Strategic Positioning
1. Parallel Phase 3 Execution in IPF-Related Chronic Cough
Trevi’s FDA-aligned plan for two pivotal Phase 3 trials in IPF-related chronic cough is a central strategic lever. The company will run a 52-week, 300-patient trial and a shorter 12-week, 130-patient confirmatory trial in parallel, both globally. This approach accelerates the path to NDA (New Drug Application), and the longer trial is powered for key secondary endpoints, including patient-reported outcomes and breathlessness, which could enhance label breadth.
2. Pipeline Expansion: Non-IPF ILD and RCC
The non-IPF ILD chronic cough program is positioned as a fast-follow indication, with an adaptive Phase 2b/3 design intended to confirm dosing and transition seamlessly into pivotal studies. This patient group more than doubles Trevi’s addressable market and leverages the same clinical and commercial infrastructure as IPF, driving operational efficiency. The RCC program advances in parallel, with dose-ranging studies designed to optimize labeling and intellectual property.
3. Capital Efficiency and Specialty Commercial Model
Trevi’s strategy leverages a specialty pharma model, focusing on indications managed by pulmonologists and minimizing commercial build-out. This enables capital-efficient launches and supports rapid uptake in high-unmet-need populations. The company’s clinical and commercial teams are tightly integrated, as evidenced by active engagement with patient advocacy groups and KOLs (Key Opinion Leaders) to drive trial enrollment and future adoption.
4. Regulatory and Labeling Strategy
The company’s proactive regulatory engagement, including the pursuit of orphan drug designation and robust secondary endpoints, aims to secure both expedited review and a differentiated label. The inclusion of patient-centric endpoints and safety data across 52 weeks aligns with evolving FDA expectations and could support broader adoption post-approval.
Key Considerations
Trevi’s 2025-2026 agenda is defined by simultaneous clinical execution and market expansion, with several factors shaping the investment thesis:
Key Considerations:
- Trial Readout Sequencing: Parallel pivotal trials in IPF-related cough target both rapid efficacy demonstration and robust safety labeling.
- Market Synergy: Non-IPF ILD program leverages the same clinical network, doubling potential reach with minimal incremental cost.
- Patient-Centric Endpoints: Secondary endpoints in breathlessness and quality of life reflect unmet needs and may drive label differentiation.
- Regulatory Adaptability: Adaptive trial designs and ongoing FDA dialogue reduce risk of regulatory surprises as guidance evolves.
- Cash Deployment Discipline: Capital is allocated to maximize value across multiple near-term catalysts, with a focus on data-driven inflection points.
Risks
Trevi faces execution risk as it launches multiple pivotal trials in parallel, including patient enrollment, site activation, and data integrity challenges. Regulatory risk remains around evolving FDA expectations for new indications and endpoints, as well as the possibility of shifting safety requirements. Competition risk is present as other IPF and ILD therapies approach market, potentially impacting trial design and commercial opportunity if timelines slip or data underperforms.
Forward Outlook
For Q2 2026, Trevi guided to:
- Initiate enrollment for the first pivotal Phase 3 IPF-related chronic cough trial (52-week, 300 patients)
- Begin RCC Phase 2b trial and advance non-IPF ILD program toward FDA meeting
For full-year 2026, management maintained guidance to:
- Deliver top-line data from the 12-week IPF Phase 3 trial and interim RCC readout
Management emphasized aggressive trial initiation and operational execution as the top priorities, with a focus on maintaining capital discipline and clinical momentum across all programs.
- Parallel trial launches to compress timelines
- Investor and Analyst Day in May to provide detailed timelines and commercial insights
Takeaways
Trevi’s clinical and financial strategy is converging in 2026, with multiple late-stage trials and a robust cash runway supporting execution. The company’s FDA-aligned approach, operational leverage across indications, and focus on patient-centric outcomes position it for value creation, but execution risk and competitive dynamics remain high.
- Parallel Clinical Execution: Running two pivotal IPF trials in parallel accelerates NDA timing and leverages operational scale, but increases complexity and enrollment risk.
- Market Expansion Opportunity: Non-IPF ILD and RCC programs are positioned as fast-follow indications, potentially doubling Trevi’s commercial opportunity with minimal incremental investment.
- Data Milestone Visibility: Investors should watch for trial initiations, enrollment curves, and interim data readouts as critical catalysts in 2026.
Conclusion
Trevi Therapeutics enters 2026 with regulatory clarity, financial strength, and a multi-pronged clinical execution plan. The next 12-18 months will be defined by pivotal trial progress and data delivery across three high-value chronic cough indications, setting up a period of heightened visibility and potential value inflection.
Industry Read-Through
Trevi’s parallel pivotal trial strategy and adaptive pipeline expansion reflect a broader trend among specialty biopharma companies seeking to maximize operational leverage and regulatory efficiency. The company’s focus on patient-reported outcomes and real-world trial design aligns with evolving FDA expectations and payor demands for evidence of meaningful benefit. For the pulmonary and rare disease sectors, Trevi’s approach highlights the importance of early regulatory alignment, capital discipline, and integrated commercial planning as key drivers of success in high-unmet-need indications. Competitors and adjacent players should monitor Trevi’s enrollment, data quality, and label differentiation as potential benchmarks for future development programs.